GLP-1 receptor agonist 14, 2758659-09-3, Stock 19.6g, Assay 99.4% 3,3-Difluoro-5-hydroxy-piperidine-1-carboxylic acid tert-butyl ester, 1258638-32-2, Stock 14.2g, Assay 99.4% CAM 833, 2758364-02-0, Stock 10.6g, Assay 98.9% (1S)- 2,2'',3,3''-tetrahydro-6,6''-diiodo-7,7...
Awesome Glp1 - (Source ⭐ 0, 📝 24/02/20 ) - Awesome resources around the GLP1 Receptor Agonist class of treatments. Sponsored by GLP1.Guide Awesome Graphql - (Source ⭐ 15K, 📝 05/06 ) - Awesome list of GraphQL Awesome Gulp - (Source ⭐ 593, 📝 18/08/20 ) - 🍹...
GLP1R library –13,938 compounds USP21 target library –2,751 compounds RNA-Binding Chemical Space library –24,000 compounds MolGluesLike compounds library –17,880 compounds USP 30 library –10,000 compounds USP7 target library –958 compounds TIM-3 library –7,000 compounds CELMoDs library ...
GLP1R library –13,938 compounds USP21 target library –2,751 compounds RNA-Binding Chemical Space library –24,000 compounds MolGluesLike compounds library –17,880 compounds USP 30 library –10,000 compounds USP7 target library –958 compounds TIM-3 library –7,000 compounds CELMoDs library ...
1 (GLP-1) Receptor Agonists Litigation, where patients are filing lawsuits against pharmaceutical companies Novo Nordisk and Eli Lilly. These lawsuits involve claims that popular GLP-1 receptor agonist medications, such as Ozempic and Mounjaro, caused serious medical complications without adequate ...
4-Di-1-ASP, 959-81-9, Stock 17.3g, Assay 99.2% ORIC-101, 2222344-98-9, Stock 14.6g, Assay 99.6% GLPG0259, 959754-85-9, Stock 15.6g, Assay 98.9% Girocitinibum, 2222137-79-1, Stock 15.1g, Assay 98.8% TC-E 5005, 959705-64-7, Stock 16.5g, Assay 99.3% ARD-2128, 2222111-...
药智数据企业版注册数据库:增设了"联合申报"、"临床试验默认许可日期"等搜索条件,让搜索页面纬度更加全面,还有热点搜索和高级条件组合检索等检索功能 等你来体验! 导出Excel 可视化分析 更多浏览方式 药智数据企业版 查看更多信息或使用更多功能前往企业版,立即体验 显示全部 显示 受理号 药品名称 ...
RECEPTOR AGONISTPROBLEM TO BE SOLVED: To provide a TGR5 (G protein coupled receptor) receptor agonist useful as a regulator for physiologic function involving TGR5 and a prophylactic/therapeutic agent for morbid state or diseases involving TGR5.ITO FUMIO伊藤 文雄...
novel URAT1 inhibitor for gout meets primary endpoint in phase II clinical trial in January 2024. In diabetes therapy area, first subject enrolled in Phase I clinical trial on GLP-1/GIP receptor agonist (THDBH120 Injections) and oral small-molecule GLP-1 receptor agonist (THDBH110 Capsules) in...
WO/2015/022420 February, 2015 GIP AND GLP-1 RECEPTOR DUAL-AGONISTS FOR THE TREATMENT OF DIABETES WO/2015/183054 December, 2015 COMPOSITION FOR TREATING DIABETES MELLITUS COMPRISING INSULIN AND A GLP-1/GLUCAGON DUAL AGONIST WO/2016/043533 March, 2016 USE OF A LONG ACTING GLP-1/GLUCAGON RECEPTOR...